2019
A novel tumor suppressing gene, ARHGAP9, is an independent prognostic biomarker for bladder cancer
Piao X, Jeong P, Yan C, Kim Y, Byun Y, Xu Y, Kang H, Seo S, Kim W, Lee J, Kim I, Moon S, Choi Y, Cha E, Yun S, Kim W. A novel tumor suppressing gene, ARHGAP9, is an independent prognostic biomarker for bladder cancer. Oncology Letters 2019, 19: 476-486. PMID: 31897161, PMCID: PMC6924059, DOI: 10.3892/ol.2019.11123.Peer-Reviewed Original ResearchNon-muscle invasive BCMuscle-invasive BCIndependent prognostic biomarkerInvasive BCPrognostic biomarkerProlonged recurrence-free survivalCancer-specific survivalCancer-specific deathRecurrence-free survivalTissues of patientsBC tissue samplesExpression of mRNAVital clinical significanceMIBC patientsBC prognosisPoor prognosisBladder cancerClinical significanceCancer tumorigenesisUseful markerLow expressionPatientsNovel tumorHigh expressionTissue samplesUrinary Cell-Free DNA IQGAP3/BMP4 Ratio as a Prognostic Marker for Non–Muscle-Invasive Bladder Cancer
Xu Y, Kim Y, Jeong P, Piao X, Byun Y, Seo S, Kang H, Kim W, Lee J, Ryu D, Choi J, Kim I, Moon S, Choi Y, Yun S, Kim W. Urinary Cell-Free DNA IQGAP3/BMP4 Ratio as a Prognostic Marker for Non–Muscle-Invasive Bladder Cancer. Clinical Genitourinary Cancer 2019, 17: e704-e711. PMID: 31088707, DOI: 10.1016/j.clgc.2019.04.001.Peer-Reviewed Original ResearchMeSH KeywordsAgedAged, 80 and overBiomarkers, TumorBone Morphogenetic Protein 4Cell-Free Nucleic AcidsDisease ProgressionFemaleGene Expression ProfilingGene Expression Regulation, NeoplasticGenes, Tumor SuppressorGTPase-Activating ProteinsHumansMaleMiddle AgedNuclear ProteinsPrognosisSurvival AnalysisUrinary Bladder NeoplasmsConceptsProgression-free survivalCox regression analysisRecurrence-free survivalDisease recurrenceBladder cancerNon-muscle invasive bladder cancerInvasive bladder cancer patientsWorse progression-free survivalMultivariate Cox regression analysisWorse recurrence-free survivalKaplan-Meier analysisKaplan-Meier curvesBladder cancer patientsRegression analysisUrinary cell-free DNAValuable novel biomarkersCell-free DNANMIBC patientsClinical outcomesCancer patientsDisease progressionPrognostic markerReal-time PCRNovel biomarkersIndependent factors
2015
Neutrophil and Lymphocyte Counts as Clinical Markers for Stratifying Low-Risk Prostate Cancer
Kwon Y, Han C, Yu J, Kim S, Modi P, Davis R, Park J, Lee P, Ha Y, Kim W, Kim I. Neutrophil and Lymphocyte Counts as Clinical Markers for Stratifying Low-Risk Prostate Cancer. Clinical Genitourinary Cancer 2015, 14: e1-e8. PMID: 26341038, PMCID: PMC5767465, DOI: 10.1016/j.clgc.2015.07.018.Peer-Reviewed Original ResearchConceptsLow-risk prostate cancerAbsolute lymphocyte countAbsolute neutrophil countLow-risk prostate cancer patientsProstate cancer patientsProstate cancerLymphocyte countANC groupLymphocyte ratioBiochemical recurrenceCancer patientsActive surveillanceHigher prostate-specific antigen levelMetastatic castration-resistant prostate cancerLow-risk PCa patientsProstate-specific antigen levelHigh absolute lymphocyte countCastration-resistant prostate cancerBiochemical recurrence-free survivalRobot-assisted radical prostatectomyAdverse pathologic outcomesAppropriate patient selectionKaplan-Meier methodRecurrence-free survivalRisk stratification tool
2014
Concern for overtreatment using the AUA/ASTRO guideline on adjuvant radiotherapy after radical prostatectomy
Kang J, Ha Y, Kim S, Yu J, Patel N, Parihar J, Salmasi A, Kim W, Kim I. Concern for overtreatment using the AUA/ASTRO guideline on adjuvant radiotherapy after radical prostatectomy. BMC Urology 2014, 14: 30. PMID: 24708639, PMCID: PMC4005471, DOI: 10.1186/1471-2490-14-30.Peer-Reviewed Original ResearchConceptsAdjuvant radiotherapyRadical prostatectomyAmerican Urological AssociationSalvage radiotherapyASTRO guidelineBiochemical progression-free survivalLocal recurrence-free survivalCox proportional hazards analysisNeoadjuvant hormonal therapyPre-operative PSAUndetectable PSA levelsProgression-free survivalPositive surgical marginsProportional hazards analysisRecurrence-free survivalMultivariate Cox analysisRadiation Oncology guidelinesSeminal vesicle invasionOutcomes of observationPathologic GSPT2-3Adjuvant treatmentHormonal therapyFree survivalPSA levels
2013
Detailed Analysis of Patients with Metastasis to the Prostatic Anterior Fat Pad Lymph Nodes: A Multi-Institutional Study
Kim I, Modi P, Sadimin E, Ha Y, Kim J, Skarecky D, Yoon D, Wambi C, Ou Y, Yuh B, Park S, Llukani E, Albala D, Wilson T, Ahlering T, Badani K, Ahn H, Lee D, May M, Kim W, Lee D. Detailed Analysis of Patients with Metastasis to the Prostatic Anterior Fat Pad Lymph Nodes: A Multi-Institutional Study. Journal Of Urology 2013, 190: 527-534. PMID: 23485503, DOI: 10.1016/j.juro.2013.02.073.Peer-Reviewed Original ResearchConceptsProstatic anterior fat padAnterior fat padLymph node metastasisMetastatic diseaseLymph nodesNode metastasisFat padPathological analysisMost patientsConcomitant pelvic lymph node dissectionPelvic lymph node dissectionBiochemical recurrence-free survivalAdjuvant/salvage therapyLymph node dissectionCharacteristics of patientsHigh-risk featuresTertiary care centerRecurrence-free survivalMulti-institutional studyPerioperative characteristicsSalvage therapyAdjuvant therapyNode dissectionAndrogen ablationClinical outcomes